NanoKnife© IRE Results We have now treated 450 patients since February 2013. All patients have been meticulously followed up (100% follow up) with high-quality MRIs and biopsies, in addition to being offered validated quality of life questionnaires. Our current outcomes for focal irreversible electroporation in the primary setting (not after radiotherapy) is: We are currently conducting […]
Focal Irreversible Electroporation Read More »
Professor Stricker’s Focal NanoKnife programme expanding throughout Australia, New Zealand, Israel and the Netherlands.
Focal NanoKnife programme Read More »
Focal therapy for selective patients with prostate cancer is a relatively new treatment for a select group of patients for the treatment of localised prostate cancer. The treatment is recommended for patients with localised prostate cancer stage T1 and T2 who are not candidates for prostatectomy because of their age, their general state of being
A recent publication by Prof Stricker’s and Prof Emberton’s group in the journal Prostate Cancer and Prostate Diseases confirmed the safety of NanoKnife focal therapy in prostate cancer. Prof Stricker feels that this is a major advance in focal therapy as irreversible electroporation has significant potential advantages over all the other energy sources currently used
